Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca M. Marin, Jann N. Sarkaria, Kendra A. Porath et al.|Neuro-Oncology|2021Cited by 81
Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain BarrierMinjee Kim, Jann N. Sarkaria, Karen E. Parrish et al.|Molecular Cancer Therapeutics|2018Cited by 40
Extension of the mutational and clinical spectrum of <i>SOX2</i> related disorders: Description of six new cases and a novel association with suprasellar teratomaPatrick R. Blackburn, Juan Carlos Zenteno, Oscar F. Chacón‐Camacho et al.|American Journal of Medical Genetics Part A|2018Cited by 11
Data from Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain BarrierMinjee Kim, Jann N. Sarkaria, J. Daniel et al.|Unknown|2023Cited by 0